EDITOR: | June 19th, 2014

Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders

| June 19, 2014 | No Comments

June 19, 2014 (Source: CNW) — Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated May 9, 2014 were elected as directors at its 2014 Annual Meeting of Shareholders, held on Wednesday June 18th, 2014. On a vote by ballot, the following 10 nominees proposed by management were elected as Directors of Oncolytics to serve until the Company`s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:

Director              For        % Withheld          %
Ger van Amersfoort 13,138,482 93.53% 909,206 6.47%
Matthew Coffey 12,772,377 90.92% 1,275,312 9.08%
Jim Dinning 11,675,341 83.11% 2,372,347 16.89%
Linda Hohol 12,509,026 89.05% 1,538,662 10.95%
Angela Holtham 12,520,502 89.13% 1,527,186 10.87%
Ed Levy 12,369,473 88.05% 1,678,215 11.95%
Mark Lievonen 11,778,509 83.85% 2,269,179 16.15%
Wayne Pisano 13,090,751 93.19% 956,937 6.81%
Robert Schultz 12,849,006 91.47% 1,198,682 8.53%
Brad Thompson 12,299,004 87.55% 1,748,684 12.45%

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company’s belief as to the potential of REOLYSIN as a cancer therapeutic; the Company’s expectations as to the success of its research and development programs in 2014 and beyond, the Company’s planned operations, the value of the additional patents and intellectual property; the Company’s expectations related to the applications of the patented technology; the Company’s expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company’s business and technologies involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


InvestorIntel.com is a leading online source of investor information that provides public market coverage for both investors and industry alike. A qualified online influencer through ... <Read more about InvestorIntel>

Copyright © 2021 InvestorIntel Corp. All rights reserved. More & Disclaimer »

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.